Citations

Clear

3942 citation(s) found for "To, Van".

Abstract 4358985: Right Ventricular Dysfunction Strongly Predicts Thromboembolism and Major Bleeding in Tetralogy of Fallot and Pulmonary Atresia with Intact Ventricular Septum
Ravi, Srekar , Ligten, Matthew Van, Bacon, Adam, Habib, Eiad , Smyth, Philip , Wang, Winston , Green, D., Alozie, Nneoma, Marshall, Chelsea, Egbe, Alexander C. , Connolly, Heidi M. , Girardo, Marlene , O'Shea, Michael, Karikalan, Suganya Arunachalam , Bacon, Adam, Baqal, Omar J , Smyth, Philip, Green, Dani, Marshall, Chelsea, Masry, Hicham El , Majdalany, David S

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4358985 Get It

Introduction: Complex congenital heart disease (CHD) patients with atrial arrhythmias have higher rates of morbidity and mortality compared to less complex CHD patients. This study aims to identify echocardiographic predictors of thromboembolism (TE) and major bleeding in patients with Tetralogy of Fallot (ToF) or Pulmonary Atresia with Intact Ventricular Septum (PA-IVS) and atrial fibrillation or flutter (AF). Methods: This cohort study included patients with ToF or PA-IVS who had a diagnosis of AF who underwent a TTE across three sites. Outcomes were incidence rate of major bleeding or TE, calculated using univariable and multivariable cox regression with interaction for anticoagulant choice and fractional area change (FAC). The HAS-BLED score was augmented with major predictors of bleeding, and receiver operator curves compared. Results: We included 300 patients (287 ToF [95.7%], 13 PA-IVS [4.3%]), mean age 45.6 years. Most received warfarin (227 [79.4%]), 40 (13%) used DOACs, and 5 (1.6%) used enoxaparin. TTE predictors of TE included large LVOT diameter ≥3cm (HR 8.92, p=0.002), small LVOT VTI (p=0.014), FAC <30% (HR 7.08, p=0.026) and moderate RV dysfunction (HR 10.75, p=0.026). Predictors of major bleeding included moderate tricuspid regurgitation (HR 2.40, p=0.022), right atrial pressure (1.12, p<0.001), severe RA enlargement (HR 2.30, p=0.048), RV mid diameter (HR 1.06, p=0.005), RV end diastolic area (HR 1.04, p=0.021), RV end systolic area (HR 1.05, p=0.016) elevated RVSP and FAC ≤45% (HR 0.37, p=0.016). Among warfarin users, impaired RV function (FAC ≤45%) was linked to reduced major bleeding events (HR 0.27, p=0.025). There was a nonsignificant trend towards higher bleeding in DOAC users with FAC >45% (HR 3.87, p=0.284), but significantly higher bleeding in DOAC users with FAC ≤45% (HR 12.41, p=0.008) vs. warfarin users with normal RV function (table 1). We developed an augmented HAS-BLED score: the standard score plus one point for moderate-to-severe pulmonic or tricuspid regurgitation and one for FAC ≤45%. This outperformed the standard HAS-BLED in predicting major bleeding (AUC 0.67 augmented vs. 0.57 un-augmented, p=0.008) (figure 1). Conclusion: Echocardiographic evidence of right heart disease is a strong predictor of major bleeding in patients with ToF or PA-IVS. FAC is a useful tool to determine excess major bleeding risk, particularly in DOAC users. Augmenting HAS-BLED with right heart parameters improves diagnostic accuracy.
Strategic documentation may enhance advanced nutrition support therapy practices
McClave, Stephen A. , Metzger, Lauri, Hiller, Lynn D. , Siegel, Sharon C. , Katz, Jennifer , Dyke, Jennifer Van, Miranda, Theresa, Hanson, Brianna, Krason, Reilly, Zirnheld, Kara, Hurt, Ryan T. , McClave, Stephen A , Siegel, Sharon, Martindale, Robert G. , Miranda, Theresa

Mayo Clinic

Nutrition in Clinical Practice | November 3, 2025 | Volume: 41 | Issue: 1 | Pages: 325-326

10.1002/ncp.70068 | PMID 41177665 Get It

Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL
Anderson, Daniela R., Gangaraju, Radhika , Sedhom, Wafik G., Hamulyák, Eva N. , Wang, Tzu‐Fei , O’Dwyer, Kristen M. , Muthiah, Chandrasekar, Liedtke, Michaela , Badar, Talha , Shimony, Shai , Robinson, Renana , Dinner, Shira, Biemond, Bart J. , Goldberg, Leah, Kapadia, Anjani , Levavi, Hannah , Bar‐Natan, Michal , Hyfte, Grace Van , Bansal, Karan, Gerrits, Anke M., Litzow, Mark R. , Luger, Selina M. , Wolach, Ofir , Shomali, William , Stock, W, O'Dwyer, Kristin , Liedtke, Michaela , Badar, Talha , Shimony, Shai , Robinson, Renana , Sanfilippo, Kristen , Derkach, Andriy , Biemond, Bart J , Levavi, Hannah , Carrier, Marc , Fulcher, Jill , Litzow, Mark R. , Luskin, Marlise R , Wolach, Ofir , Shomali, William , Zwicker, Jeffrey I , Carney, Brian J. , Derkach, Andriy , Nemirovsky, David , Carrier, Marc , Murthy, Guru Subramanian Guru , Stock, Wendy, Leader, Avi

Mayo Clinic

Blood Advances | October 31, 2025 | Volume: 10 | Issue: 3 | Pages: 593-603

10.1182/bloodadvances.2025017862 | PMID 41170879 Get It

Abstract The incidence of venous thromboembolism (VTE) in patients with acute lymphoblastic leukemia (ALL) receiving asparaginase-based induction is high despite primary thromboprophylaxis. Our aim was to derive and externally validate a VTE risk prediction model in patients with ALL receiving asparaginase-based induction. We conducted a multicenter retrospective cohort study of patients (aged ≥18 years) with newly diagnosed ALL receiving asparaginase-based induction. The derivation and external validation cohorts included 306 and 94 patients, respectively. Primary outcome was VTE at any site. A cause-specific Cox proportional hazards model stratified by thromboprophylaxis and center was performed to identify VTE risk factors in the derivation cohort. A risk prediction model for VTE at 30 days was derived using variables with P value &lt; .05 in the multivariable model and was tested in the validation cohort. VTE risk factors on multivariable analysis in the derivation cohort included D-dimer ≥1 μg fibrinogen equivalent unit per mL (hazard ratio [HR], 2.64; 95% confidence interval [CI], 1.07-6.5) and hemoglobin (HR for each 1 g/dL increment, 1.19; 95% CI, 1.06-1.34) at ALL diagnosis. A VTE risk score based on these variables distinguished between a 4% (95% CI, 0.72-12) and 20% (95% CI, 14-27) 30-day cumulative incidence of VTE in the derivation cohort, with similar findings in the validation cohort (area under the curve, 0.56). The negative predictive value for VTE at 30 days was 96% and 93% in the derivation and validation cohorts, respectively, and the positive predictive value was 20% in both. We derived and validated a model using D-dimer and hemoglobin, which stratifies VTE risk in patients with ALL receiving asparaginase-based induction.
Protecting the Contralateral Palatine Tonsil
Chen, Michelle , Abel, Kathryn M. Van , Van Abel, Kathryn M , Rettig, Eleni M.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | October 30, 2025 | Volume: 152 | Issue: 1 | Pages: 101

10.1001/jamaoto.2025.3318 | PMID 41165672 Get It

Proton Beam vs Intensity-Modulated Radiotherapy in Olfactory Neuroblastoma
Tang, Anthony , Krippaehne, Elise , Roozdar, Pooya, Goetschel, Kaitlin , Champagne, Pierre‐Olivier , Fernandez‐Miranda, Juan C. , Gardner, Paul , Hwang, Peter H. , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Snyderman, Carl H., Thorp, Brian D. , Zenonos, Georgios A. , Zwagerman, Nathan T. , Wang, Eric W., Olson, Brennan , Patel, Zara , Hwang, Peter H , Adida, Samuel , Donohue, Jack K. , Gago, Guilherme , Almeida, João Paulo , Nayak, Jayakar V. , Patel, Chirag, Pinheiro‐Neto, Carlos , Routman, David M. , Snyderman, Carl H , Gompel, Jamie J. Van , Wilke, Christopher , Wang, Eric W , Geltzeiler, Mathew , Choby, Garret

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | October 30, 2025 | Volume: 152 | Issue: 1 | Pages: 60

10.1001/jamaoto.2025.3816 | PMID 41165699 Get It

Importance Adjuvant radiotherapy can improve locoregional control and survival in patients with olfactory neuroblastoma (ONB), particularly with advanced-stage and histologic-grade disease. Standard radiotherapy treatment is with intensity-modulated radiotherapy (IMRT). Proton beam radiotherapy (PBRT) provides theoretical advantages in greater sparing of dose to uninvolved organs at risk. Objective To investigate if there are differences in the effectiveness and radiation treatment–related adverse events (RTAEs) between adjuvant IMRT and PBRT for patients with ONB. Design, Setting, and Participants This propensity score–matched cohort study included patients with ONB treated between February 2005 and April 2021 with either IMRT or PBRT at 9 academic tertiary care centers in North America. Patients were matched 1:2 based on age, modified Kadish stage, and Hyams grade. Data were analyzed from July 2024 to January 2025. Exposure Adjuvant IMRT or adjuvant PBRT. Main Outcomes and Measures Local recurrence-free survival (RFS), any RFS, and overall survival (OS). RTAEs, ie, grade 2 events or higher based on Common Terminology Criteria for Adverse Events, were recorded for both modalities. Results Of 54 included patients, 27 (50%) were female, and the mean (SD) age was 46.2 (15.4) years. A total of 18 were treated with PBRT and 36 were treated with IMRT. Most patients had modified Kadish stage C disease (33 of 54 [61%]), and 24 patients (44%) had Hyams grade III or IV disease. The RTAE rate was 20% (8 of 40); IMRT had a rate of 21% (6 of 29), and PBRT had a rate of 18% (2 of 11). The difference in the point estimates for 10-year RFS showed a potential clinical benefit favoring IMRT, although the wide confidence interval indicates uncertainty (10-year RFS: IMRT, 63.3%; 95% CI, 44.6-89.8; PBRT, 37.8%; 95% CI, 14.2-100; difference, 25.5 percentage points; 95% CI, −17.6 to 68.6). There were no clinically meaningful differences in 10-year local RFS (IMRT, 75.6%; 95% CI, 59.8-95.4; PBRT, 72.7%; 95% CI, 45.2-100; difference, 2.9 percentage points; 95% CI, −35.9 to 41.7) or 10-year OS (IMRT, 61.8%; 95% CI, 42.8-89.1; PBRT, 57.1%; 95% CI, 24.3-100; difference, 4.7 percentage points; 95% CI, −49.2 to 58.6), although wide confidence intervals indicate considerable uncertainty. Conclusions and Relevance Due to the imprecision of estimates, no definitive conclusions can be made regarding the comparative effectiveness of IMRT vs PBRT for patients with ONB. These preliminary data may inform the design of appropriately powered prospective studies evaluating the efficacy of PBRT vs IMRT in this population.
Prioritization of outcome measures in regional anesthesia research
El‐Boghdadly, Kariem , Ayad, Amany E. , Memtsoudis, Stavros G. , Schreiber, Kristin L. , Radcliffe, Gillian , Rivett, Kate, Princova, Zuzana, Adhikary, Sanjib Das , Candido, Kenneth D., Coppens, Steve , Hanna, Marie N. , Kandil, Enas , Kohan, Lynn , Muse, Iyabo O. , Nsiri, Afak , Pasternak, Jeffrey J., Tolba, Reda, Wolmarans, Morné , Elkassabany, Nabil , Memtsoudis, Stavros G , Schreiber, Kristin L , Adhikary, Sanjib , Albrecht, Eric , Bowness, James , Coppens, Steve , Gupta, Rajnish K , Johnson, Rebecca L , Kohan, Lynn R , Kopp, Sandra , Lobo, Clara , Moka, Eleni , Pino, Carlos A , Singh, Vinita , Van de Putte, Peter B C , Wolmarans, Morné , Elkassabany, Nabil M , El-Boghdadly, K , Narouze, Samer , Myles, Paul S. , Albrecht, Éric , Gupta, Rajnish K. , Johnson, Rebecca L. , Kopp, Sandra L. , Lobo, Clara , Μoka, Εleni , Pino, Carlos A. , Singh, Vinita , Theron, Andre

Mayo Clinic

Regional Anesthesia & Pain Medicine | October 29, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107087

10.1136/rapm-2025-107087 | PMID 41151978 Get It

Background Outcome selection in regional anesthesia and acute pain research is inconsistent, often lacking patient-centered priorities and validated instruments. We aimed to prioritize key outcomes and propose suitable measurement tools to improve the quality, consistency, and relevance of regional anesthesia research. Methods We conducted a multiround Delphi process, including two electronic voting rounds, a multiday in-person meeting, and a patient panel. Experts and patients evaluated existing and proposed outcomes for importance, validity, and relevance. Outcomes reaching ≥70% agreement were prioritized, and appropriate measurement instruments were identified. Results Thirty-two experts and three patients participated. Across three Delphi rounds, 10 outcomes were prioritized for future regional anesthesia research: seven efficacy outcomes (pain scores; opioid consumption; Brief Pain Inventory; functional outcomes; cognitive function; length of stay; block duration); two multidimensional outcomes (quality of recovery and development of a regional anesthesia-specific quality-of-recovery instrument); one safety outcome (chronic postsurgical pain). Patients prioritized cognitive recovery, function, chronic pain, and pain scores. Conclusions This consensus-based, patient-centered framework defines the core priorities for future regional anesthesia and acute pain research. Future work should focus on developing and validating a regional anesthesia-specific quality-of-recovery instrument, refining multidimensional measures such as functional recovery, cognitive outcomes, and the Brief Pain Inventory, and standardizing the reporting of chronic pain and opioid-related outcomes. Adoption of these priorities will enhance methodological consistency, comparability, and patient relevance in future clinical trials.
Modified Clavien-Dindo Classification for Adverse Events in Otolaryngology–Head and Neck Surgery
Hidalgo, C. , Martin, Eliot J., Eyassu, Daniel G. , Hernandez-Herrera, Gabriel A. , Jenkins, Sarah M. , Chweya, Cynthia M. , Sankar, George B., Carlson, Matthew L. , Moore, Eric J. , Wiedermann, Joshua P. , Abel, Kathryn M. Van , Hidalgo, Cecelia M, Bayan, Semirra L. , Van Abel, Kathryn M , Hernandez Herrera, Gabriel A , Hamilton, Grant

Mayo Clinic

JAMA Network Open | October 27, 2025 | Volume: 8 | Issue: 10 | Pages: e2539761

10.1001/jamanetworkopen.2025.39761 | PMID 41143791 Get It

Importance Adverse events in otolaryngology–head and neck surgery (OHNS) are inconsistently reported. The Clavien-Dindo Classification has been modified and validated in several surgical subspecialties but has yet to be validated in OHNS. Objective To create and validate a modified Clavien-Dindo Classification for OHNS that reflects the severity and duration of harm for complications experienced by patients undergoing OHNS. Design, Setting, and Participants This is a multicenter survey study of subject matter experts (SMEs) from OHNS subspecialties from academic institutions within the US. A literature review identified publications reporting surgical complications in OHNS in the English language between January 2019 and April 2020. Complications were summarized and used to inform a modified Clavien-Dindo Classification. Feedback from internal SMEs was incorporated. Thirty-five clinical vignettes were created, and an electronic survey was sent to SMEs at outside institutions. Each SME was randomly assigned to 1 of 4 groups to evaluate 8 to 9 vignettes. The survey was conducted in September 2023, and data were analyzed from February to May 2024. Exposure Participation in the electronic survey. Main Outcomes and Measures Vignette scores were assessed and the Comprehensive Complication Index (CCI) calculator was used to assess cumulative morbidity. The scale is based on the grading by the Clavien-Dindo Classification and reflects overall morbidity on a scale from 0 (no complication) to 100 (death). Variability of the CCIs between reviewers, the primary outcome, was summarized with the SD. The percentage of reviewers with a high (≥26.2) or low (&amp;lt;26.2) CCI within a vignette was reported. Reliability was summarized using Krippendorff α. Results Of 106 SMEs, 43 (response rate, 40.6%) completed at least 1 vignette. Eighteen of 35 vignettes (51.4%; 95% CI, 34.9%-68.0%) had unanimous high CCI, and 8 of 35 vignettes (22.9%; 95% CI, 8.9%-36.8%) had unanimous low CCI (overall categorical agreement, 74.3%; 95% CI, 59.8%-88.8%). On average, the Krippendorff α was 0.74, indicating moderate reliability. A total of 21 850 OHNS complications were reviewed and categorized as surgical or medical with 12 including subcategorization for specificity. Each category was then assigned a modified OHNS Clavien Dindo classification grade. Conclusions and Relevance In this survey study of OHNS experts, a modified OHNS Clavien-Dindo Classification was developed and validated using case vignettes. The modified Clavien-Dindo Classification provided a granular subcategorization for each complication category and grade, duration of harm, and an overall summary complication score (CCI). Results suggest the modified OHNS Clavien-Dindo Classification reliably differentiated between high-grade and low-grade OHNS complications and could be utilized for assessing surgical outcomes.
(010) UNVEILING THE IMPACT OF BODY MASS INDEX ON OVERALL OUTCOMES OF INFLATABLE PENILE PROSTHESIS PLACEMENT: INSIGHTS FROM AN INTERNATIONAL, MULTI-CENTER INVESTIGATION
Hammad, MAM, Gross, MS, Andrianne, Robert, Burnett, AL, Gross, Kelli, Hatzichristodoulou, G, Lentz, A, Modgil, Vaibhav , Perito, P, Hotaling, JM, Park, SH, Pearce, Ian , Sadeghi‐Nejad, Hossein , Sempels, Maxime, Suarez-Sarmiento, A, Renterghem, Katrien Van, Warner, J, Ziegelmann, Matthew , Hsieh, TC, Karthikeyan, Hridhay, Simhan, Jay , Yafi, FA, collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW, Hammad, Muhammed , Miller, Jake A. , Chawareb, Elia Abou , Amini, Erfan , Hatzichristodoulou, Georgios , Lentz, A, Osmonov, D, Suarez‐Sarmiento, Alfredo, Azad, Babak Kazemzadeh , Jenkins, Lawrence C. , Jones, James M. , collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW

Mayo Clinic

The Journal of Sexual Medicine | October 25, 2025 | Volume: 21 | Issue: Supplement_6 | Pages: No page available

10.1093/jsxmed/qdae161.010 Get It

Abstract Introduction Obesity, defined as an elevated Body Mass Index (BMI) &gt;30, is a prevalent public health concern with far-reaching implications for various medical procedures and outcomes. In the context of inflatable penile prosthesis placement (IPP), where patient well-being and surgical success are of paramount importance, the impact of obesity on postoperative and intraoperative complications warrants thorough investigation. Objective Our study aimed to investigate the impact of BMI on both postoperative and intraoperative complications in an international, multi-institutional cohort of patients who underwent IPP placement. Methods We performed a retrospective chart review of 4398 cases. These cases were divided into two distinct groups based on BMI: less than 30 (n = 2260) and greater than or equal to 30 (n = 2138). The study assessed various surgical factors as well as complications, including overall complications, corporal scarring, incontinence, intraoperative complications, proximal perforation, distal perforation, proximal crossover, distal crossover, and urethral injury. Results Our analysis revealed that there were no statistically significant differences in intraoperative or postoperative complications between the two BMI categories. Notably, proximal corporal measurement was significantly higher for &gt;30 BMI group (9.55 +/−2.18) compared to &lt;30 BMI group (9.14 +/−2.19), (p = &lt; 0.001). The incidence rates for overall complications (30.2% vs. 28.7%; p = 0.164), corporal scarring (18.2% vs. 16.7%; p = 0.36), incontinence (3.53% vs. 3.13%; p = 0.076), intraoperative complications (1.94% vs. 1.68%; p = 0.253), and specific complications all exhibited no significant differences. Similarly, post-operative complications, including both non- infectious (6.99% vs. 6.22%; p = 0.215) and infectious (2.61% vs. 1.87%; p = 0.165) complications, did not significantly vary between BMI categories. Conclusions Our findings indicate that BMI does not exert a statistically significant influence on postoperative and intraoperative complications in the context of high-volume prosthetic urology. In the absence of any other differences between patients of differing BMIs, surgeons may need to be mindful of pump tubing length concerns in obese patients. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Coloplast, Clarus Therapeutics, Antares Pharma, Acerus.
Genome-wide association studies identify 77 loci for suicidality and provide novel biological insights
Colbert, Sarah M. C. , Koromina, Maria, Hatoum, Alexander S, Stephenson, Mallory, Edwards, Alexis C, Johnson, Emma C, Qin, Xuejun, Shabalin, Andrey A, Ito, Lucas T, O’Connell, Kevin S, Harder, Arvid, Hjerling-Leffler, Jens, Kim, Min Ji, Otsuka, Ikuo, Vilar-Ribó, Laura, Agrawal, Arpana, Alda, Martin, Alfredsson, Lars, Aliev, Fazil, Andlauer, Till FM, Arango, Celso, Arntz, Arnoud, Awasthi, Swapnil, Ayinde, Olatunde O, Bacanu, Silviu-Alin, Barr, Peter B, Bau, Claiton HD, Baune, Bernhard T, Beckham, Jean C, Bejan, Cosmin A, Belangero, Sintia, Berger, Klaus, Biernacka, Joanna M, Bogdan, Ryan, Boomsma, Dorret I, Børglum, Anders D, Bourassa, Kyle J, Braff, David L, Braun, Alice, Bressan, Rodrigo A, Brueckl, Tanja M, Budde, Monika, Cabrera-Mendoza, Brenda, Carpiniello, Bernardo, Ceja, Zuriel, Cervilla, Jorge A, Chang, Chiao-Erh, Chaumette, Boris, Cheon, Myeong Jae, Cichon, Sven, Coleman, Jonathan RI, Coon, Hilary, Copeland, William E, Czamara, Darina, Dalkner, Nina, Dannlowski, Udo, David, Friederike S, Demontis, Ditte, Florio, Arianna Di, Diaconu, Carmen C, Dick, Danielle M, Dikeos, Dimitris, Djurovic, Srdjan, Edenberg, Howard J, Erlangsen, Annette, Euler, Sebastian, Falkai, Peter, Fanelli, Giuseppe, Fellendorf, Frederike T, Ferentinos, Panagiotis, Fernandez-Aranda, Fernando, Forstner, Andreas J, Frei, Oleksandr, Fries, Gabriel R, Fullerton, Janice M, Gaine, Marie E, Galfalvy, Hanga C, Galimberti, Marco, Garcia-Aymerich, Judith, Garrett, Melanie E, Gawlik, Micha, Gelernter, Joel, Gordon-Smith, Katherine, Gorelik, Aaron J, Gorwood, Philip, Grabe, Hans J, Green, Melissa J, Grigoroiu-Serbanescu, Maria, Gupta, Priya, Gutiérrez, Blanca, Guzman-Parra, Jose, Han, Seonggyun, Haram, Marit, Hauser, Elizabeth R, Heilbronner, Urs, Herpertz, Sabine C, Herrera-Imbroda, Jesús, Hesselbrock, Victor M, Hishimoto, Akitoyo, Holla, Bharath, Izotova, Anastasia, Jang, Yoonjeong, Jimenez-Murcia, Susana, Jones, Lisa A, Jonsson, Lina, Kang, JooEun, Kang, Joon Ho, Keel, Pamela K, Kim, Jaeyoung, Kim, Dongjun, Kircher, Tilo, Kirov, George, Kraft, Julia, Kramer, John, Kranzler, Henry R, Kuo, Po-Hsiu, Kurvits, Siim, Lai, Dongbing, Lake, Marilyn T, Landén, Mikael, Lannoy, Séverine, Law, Matthew H, Lee, Byung-Chul, Lee, Young Kee, Lehto, Kelli, Levey, Daniel F, Lewis, Cathryn M, Li, Qingqin S, Liao, Calwing, Lind, Penelope A, Lochner, Christine, Lori, Adriana, Maes, Hermine HM, Mahadevan, Jayant, Manchia, Mirko, Mars, Becky, Martin, Nicholas G, Martorell, Lourdes, McIntosh, Andrew M, McMain, Shelley F, McQuillin, Andrew, Medland, Sarah E, Mitchell, Philip B, Molina, Esther, Monson, Eric T, Mufford, Mary S, Muntané, Gerard, Musil, Richard, Myung, Woojae, Neagu, Ana Iulia, Nielsen, Trine T, Nöthen, Markus M, Nunez, Yaira Z, Nurnberger, John I, Okazaki, Satoshi, Olsen, Catherine M, Ophoff, Roel A, Owen, Michael J, Pan, Pedro M, Papiol, Sergi, Pascual, Juan C, Patrinos, George P, Pawlak, Joanna M, Penninx, Brenda WJH, Pérez-Gutiérrez, Ana M, Perroud, Nader, Peterson, Roseann E, Pisanu, Claudia, Pistis, Giorgio, Porjesz, Bernice, Posthuma, Danielle, Powers, Abigail, Preisig, Martin, Purushottam, Meera, Reif, Andreas, Reininghaus, Eva Z, Rentería, Miguel E, Ripke, Stephan, Ripperger, Michael A, Rivera, Margarita, Roberts, Emily K, Roberts, Gloria, Rødevand, Linn, Roepke, Stefan, Rovaris, Diego L, Salum, Giovanni A, Sanders, Alan R, Santoro, Marcos L, Sawyers, Chelsea, Scherer, Stephen W, Schilling, Claudia, Schmahl, Christian, Schofield, Peter R, Schulze, Thomas G, Scott, Laura J, Serretti, Alessandro, Shadrin, Alexey, Shirai, Toshiyuki, Smeland, Olav B, Smoller, Jordan W, Sokolowski, Marcus, Sonuga-Barke, Edmund J, Squassina, Alessio, Starnawska, Anna, Steen, Nils Eiel, Stein, Dan J, Stein, Frederike, Stein, Murray B, Streit, Fabian, Sud, Reeteka, Sullivan, Patrick F, Terao, Chikashi, Toma, Claudio, Tondo, Leonardo, Turecki, Gustavo, Uher, Rudolf, Ursano, Robert J, Auwera, Sandra Van der, Vawter, Marquis P, Paska, Alja Videtic, Vilella, Elisabet, Vincent, John B, Viswanath, Biju, Vladimirov, Vladimir, Wasserman, Danuta E, Weickert, Thomas W, Whiteman, David C, Willour, Virginia L, Wiström, Erik D, Witt, Stephanie H, Won, Hong-Hee, Wootton, Robyn E, Zai, Clement C, Zhang, Jian, Zillich, Lea, MGL, CVEDA and, Andreassen, Ole A, Palmer, Abraham A, Sanchez-Roige, Sandra, Mann, J John, Kimbrel, Nathan A, Ashley-Koch, Allison E, Docherty, Anna R. , Mullins, Niamh , Roberts, Gloria , Pisanu, Claudia , Holla, Bharath , Fanelli, Giuseppe , Ruderfer, Douglas , Docherty, Anna R , Mullins, Niamh , Pisanu, Claudia , Koromina, Maria, Hatoum, Alexander S, Stephenson, Mallory, Edwards, Alexis C, Johnson, Emma C, Qin, Xuejun, Shabalin, Andrey A, Ito, Lucas T, O’Connell, Kevin S, Harder, Arvid, Hjerling-Leffler, Jens, Kim, Min Ji, Otsuka, Ikuo, Vilar-Ribó, Laura, Agrawal, Arpana, Alda, Martin, Alfredsson, Lars, Aliev, Fazil, Andlauer, Till FM, Arango, Celso, Arntz, Arnoud R. , Awasthi, Swapnil, Ayinde, Olatunde O, Bacanu, Silviu-Alin, Barr, Peter B, Bau, Claiton HD, Baune, Bernhard T, Beckham, Jean C, Bejan, Cosmin A, Belangero, Sintia, Berger, Klaus, Biernacka, Joanna M, Bogdan, Ryan, Boomsma, Dorret I , Børglum, Anders D, Bourassa, Kyle J, Braff, David L, Braun, Alice, Bressan, Rodrigo A, Brueckl, Tanja M, Budde, Monika, Cabrera-Mendoza, Brenda, Carpiniello, Bernardo, Ceja, Zuriel, Cervilla, Jorge A, Chang, Chiao-Erh, Chaumette, Boris , Cheon, Myeong Jae, Cichon, Sven, Coleman, Jonathan RI, Coon, Hilary, Copeland, William E, Czamara, Darina, Dalkner, Nina, Dannlowski, Udo, David, Friederike S, Demontis, Ditte, Florio, Arianna Di, Diaconu, Carmen C, Dick, Danielle M, Dikeos, Dimitris, Djurovic, Srdjan, Edenberg, Howard J, Erlangsen, Annette , Euler, Sebastian, Falkai, Peter , Fellendorf, Frederike T, Ferentinos, Panagiotis, Fernandez-Aranda, Fernando, Forstner, Andreas J, Frei, Oleksandr, Fries, Gabriel R, Fullerton, Janice M, Gaine, Marie E, Galfalvy, Hanga C, Galimberti, Marco, Garcia-Aymerich, Judith, Garrett, Melanie E, Gawlik, Micha, Gelernter, Joel, Gordon-Smith, Katherine, Gorelik, Aaron J, Gorwood, Philip , Grabe, Hans J, Green, Melissa J, Grigoroiu-Serbanescu, Maria, Gupta, Priya, Gutiérrez, Blanca, Guzman-Parra, Jose, Han, Seonggyun, Haram, Marit, Hauser, Elizabeth R, Heilbronner, Urs , Herpertz, Sabine C, Herrera-Imbroda, Jesús, Hesselbrock, Victor M, Hishimoto, Akitoyo, Izotova, Anastasia, Jang, Yoonjeong, Jimenez-Murcia, Susana, Jones, Lisa A, Jonsson, Lina, Kang, JooEun, Kang, Joon Ho, Keel, Pamela K, Kim, Jaeyoung, Kim, Dongjun, Kircher, Tilo, Kirov, George, Kraft, Julia, Kramer, John, Kranzler, Henry R, Kuo, Po-Hsiu, Kurvits, Siim, Lai, Dongbing, Lake, Marilyn T, Landén, Mikael, Lannoy, Séverine, Law, Matthew H, Lee, Byung-Chul, Lee, Young Kee, Lehto, Kelli, Levey, Daniel F, Lewis, Cathryn M, Li, Qingqin S, Liao, Calwing, Lind, Penelope A, Lochner, Christine, Lori, Adriana, Maes, Hermine HM, Mahadevan, Jayant, Manchia, Mirko, Mars, Becky, Martin, Nicholas G, Martorell, Lourdes, McIntosh, Andrew M, McMain, Shelley F, McQuillin, Andrew, Medland, Sarah E, Mitchell, Philip B, Molina, Esther, Monson, Eric T, Mufford, Mary Sophia , Muntané, Gerard, Musil, Richard, Myung, Woojae, Neagu, Ana Iulia, Nielsen, Trine T, Nöthen, Markus M, Nunez, Yaira Z, Nurnberger, John I, Okazaki, Satoshi, Olsen, Catherine M, Ophoff, Roel A. , Owen, Michael J, Pan, Pedro M, Papiol, Sergi, Pascual, Juan C, Patrinos, George P, Pawlak, Joanna M, Penninx, Brenda WJH, Pérez-Gutiérrez, Ana M, Perroud, Nader, Peterson, Roseann E, Pistis, Giorgio, Porjesz, Bernice, Posthuma, Danielle, Powers, Abigail, Preisig, Martin, Purushottam, Meera, Reif, Andreas, Reininghaus, Eva Z, Rentería, Miguel E, Ripke, Stephan, Ripperger, Michael A, Rivera, Margarita, Roberts, Emily K, Roberts, Gloria, Rødevand, Linn, Roepke, Stefan, Rovaris, Diego L, Salum, Giovanni A, Sanders, Alan R, Santoro, Marcos L, Sawyers, Chelsea, Scherer, Stephen W, Schilling, Claudia, Schmahl, Christian, Schofield, Peter R, Schulze, Thomas , Scott, Laura J, Serretti, Alessandro, Shadrin, Alexey, Shirai, Toshiyuki, Smeland, Olav B, Smoller, Jordan W, Sokolowski, Marcus , Sonuga-Barke, Edmund J, Squassina, Alessio, Starnawska, Anna, Steen, Nils Eiel, Stein, Dan J, Stein, Frederike, Stein, Murray B, Streit, Fabian, Sud, Reeteka, Sullivan, Patrick F, Terao, Chikashi, Toma, Claudio, Tondo, Leonardo, Turecki, Gustavo, Uher, Rudolf, Ursano, Robert J, Auwera, Sandra Van der, Vawter, Marquis P, Paska, Alja Videtic, Vilella, Elisabet, Vincent, John B, Viswanath, Biju, Vladimirov, Vladimir, Wasserman, Danuta E, Weickert, Thomas W, Whiteman, David C, Willour, Virginia L, Wiström, Erik D, Witt, Stephanie H, Won, Hong-Hee, Wootton, Robyn E, Zai, Clement C, Zhang, Jian, Zillich, Lea, MGL, CVEDA and, Andreassen, Ole A, Palmer, Abraham A, Sanchez-Roige, Sandra, Mann, J John, Kimbrel, Nathan A, Ashley-Koch, Allison E

Mayo Clinic

No container title available | October 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.10.22.25338076 | PMID 41282879 Get It

ABSTRACT Suicidality contributes substantially to global morbidity and mortality, yet despite its heritability, its biological etiology remains largely elusive. We conducted multi-ancestry genome-wide association study meta-analyses of suicidal ideation (259,747 cases), suicide attempt (64,993 cases), suicide death (9,197 cases), and suicidal behavior (suicide attempt/ death, 75,300 cases), across 54 cohorts (e.g., the Psychiatric Genomics Consortium, Million Veteran Program, UK Biobank). We identified 77 significant loci across meta-analyses, including 59 previously unreported for suicidality. SNP-based heritability ranged from 2.0-6.7% and there were strong, yet incomplete, genetic correlations between suicidality phenotypes (0.70-0.88). Fine-mapping prioritized putative causal SNPs and 20 credible genes. Enrichment analyses implicated synaptic pathways and neuronal populations predominantly in subcortical brain regions (e.g., amygdala excitatory, medium spiny, hippocampal CA1-3). Together, these findings establish suicidality as a polygenic set of traits with both shared and distinct genetic influences, providing a foundation for future studies of suicide biology and etiology.
SUN-061 Recovery of Adrenal Insufficiency After Surgical Remission of Endogenous Hypercortisolism: A Prospective Cohort Study
Chacko, Shireen R , Sharma, Shubhangi Sharma , Ahmadian, Sarina , Achenbach, Sara J., Atkinson, Elizabeth J. , Fell, Vanessa , Saini, Jasmine , Gompel, Jamie J. Van , Young, William F. , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.1646 Get It

Abstract Disclosure: S.R. Chacko: None. J. Saini: None. S. Sharma Sharma: None. S. Ahmadian: None. S.J. Achenbach: None. E. Atkinson: None. V. Fell: None. J.J. Van Gompel: None. W.F. Young, Jr.: None. I. Bancos: None. Context: Evidence on the duration of postoperative adrenal insufficiency (AI) in patients with endogenous hypercortisolism is scarce. Objective: To determine the duration of postoperative AI and to identify factors associated with the duration of AI in patients undergoing surgery for endogenous hypercortisolism.Methods: We conducted a single center prospective cohort study, 2019-2024, of patients with endogenous hypercortisolism [Cushing syndrome (CS) or mild autonomous cortisol secretion (MACS)] treated with surgery. Associations of demographics, BMI, clinical and biochemical hypercortisolism severity, subtype of hypercortisolism, presurgical hypercortisolism duration and glucocorticoid type in relation to duration of AI were investigated. Results: The 110 patients [36% MACS, 46% pituitary CS, 15% adrenal CS, 3% ectopic CS, median age 50 years (IQR: 40-60), 82% women] who developed postsurgical AI were followed for a median duration of 26 months (IQR: 15-38). By the end of follow up, 96 patients (87%) had recovery of AI. The median time to recovery of AI was shorter in MACS vs. Overt Cushing syndrome (3.0 months (95% CI: 2.5-6.2) vs. 12.3 months (95% CI 9.0-17.3), P =0.002). Biochemical severity score (r=0.32, P=0.002) and duration of preoperative hypercortisolism symptoms (r=0.29, P=0.005), but not age, sex, BMI, clinical severity, or glucocorticoid type were associated with the duration of AI. We found no differences in the duration of AI between patients with ACTH-dependent vs ACTH-independent CS (12.3 months (95% CI: 6.0-17.2) vs 13.9 months (95% CI: 9.0-25.5), P =0.7).Conclusion: In this interim analysis, we showed that after surgical remission of endogenous hypercortisolism, duration of postoperative AI was longer in CS compared to MACS. Additionally, higher biochemical hypercortisolism severity score and a longer duration of symptoms suggestive of hypercortisolism were associated with a longer duration of postoperative AI. Presentation: Sunday, July 13, 2025